Regulus Therapeutics Inc. stock is up 7.2% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.67% of the previous 11 November’s closed higher than October.
Regulus Therapeutics Inc. engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.